Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial

Accepted/In Press date: 28 November 2019

e-pub ahead of print date: 10 January 2020

Published date: 1 July 2020

Additional Information: Funding Information: This work was supported by the European Clinical Research Institute, which received unrestricted Grants from Biosensors International, AstraZeneca, and the Medicines Company. Funding Information: Dr. Tomaniak reports lecture fee from Astra Zeneca, outside the submitted work. Dr. Chichareon reports Grants from biosensons, outside the submitted work. Dr. Modolo reports Grants from Biosensors, outside the submitted work. Dr. Curzen reports Grants and personal fees from Boston Scientific, Grants and personal fees from Heartflow, Grants and personal fees from Haemonetics, outside the submitted work. Dr. Haude reports institutional Grant/research support from Biotronik AG, Abbott Vascular, Cardiac Dimensions, Volcano, Lilly and consultant/speaker´s bureau: Biotronik AG, Abbott Vascular, Cardiac Dimensions. Dr. Montalescot has received research Grants to the institution or consulting/lecture fees from Abbott, Amgen, Actelion, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women’s Hospital, Cardiovascular Research Foundation, Daiichi-Sankyo, Idorsia, Lilly, Europa, Elsevier, Fédération Française de Cardiologie, ICAN, Medtronic, Journal of the American College of Cardiology, Lead-Up, Menarini, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Sanofi, Servier, The Mount Sinai School, TIMI Study Group, and WebMD. Dr. Angiolillo reports Grants and personal fees from Amgen, Grants and personal fees from Aralez, Grants and personal fees from Bayer, Grants and personal fees from Biosensors, Grants and personal fees from Boehringer Ingelheim, Grants and personal fees from Bristol-Myers Squibb, Grants and personal fees from Chiesi, Grants and personal fees from Daiichi-Sankyo, Grants and personal fees from Eli Lilly, personal fees from Haemonetics, Grants and personal fees from Janssen, Grants and personal fees from Merck, personal fees from PhaseBio, personal fees from PLx Pharma, personal fees from Pfizer, Grants and personal fees from Sanofi, personal fees from The Medicines company, Grants and personal fees from CeloNova, personal fees from St Jude Medical, Grants from CSL Behring, Grants from Eisai, Grants from Gilead, Grants from Idorsia Pharmaceuticals Ltd, Grants from Matsutani Chemical Industry Co., Grants from Novartis, Grants from Osprey Medical, Grants from Renal Guard Solutions, Grants from Scott R. MacKenzie Foundation, Grants from NIH/NCATS Clinical and Translational Science Award to the University of Florida UL1 TR000064 and NIH/NHGRI U01 HG007269, Grants and personal fees from Astra Zeneca, outside the submitted work. Dr. Capodanno reports personal fees from Bayer, personal fees from AstraZeneca, personal fees from Sanofi Aventis, personal fees from Baehringer, personal fees from Daiichi Sankyo, outside the submitted work. Dr. Storey reports personal fees from Bayer, personal fees from Bristol-Myers Squibb/Pfizer, Grants and personal fees from AstraZeneca, personal fees from Novartis, personal fees from Idorsia, Grants and personal fees from Thromboserin, personal fees from Haemonetics, personal fees from Amgen, Grants and personal fees from Glycardial Diagnostics, outside the submitted work. Dr. Hamm reports personal fees from AstraZeneca, outside the submitted work. Dr. Vranckx reports personal fees from AstraZeneca and the Medicines Company during the conduct of the study and personal fees from Bayer Health Care, Terumo, and Daiichi-Sankyo outside the submitted work. Dr. Valgimigli reports Grants and personal fees from Abbott, personal fees from Chiesi, personal fees from Bayer, personal fees from Daiichi Sankyo, personal fees from Amgen, Grants and personal fees from Terumo, personal fees from Alvimedica, Grants from Medicure, Grants and personal fees from AstraZeneca, personal fees from Biosensors, outside the submitted work. Dr. Windecker’s institution has research contracts with Abbott, Amgen, Bayer, Biotronik, Boston Scientific, Edwards Lifesciences, Medtronic, St Jude Medical, Symetis SA, and Terumo outside the submitted work. Dr. Onuma has received consultancy fees from Abbott Vascular outside the submitted work. Dr. Serruys has received personal fees from Abbot Laboratories, AstraZeneca, Biotronik, Cardialysis, GLG Research, Medtronic, Sino Medical Sciences Technology, Société Europa Digital Publishing, Stentys France, Svelte Medical Systems, Philips/Volcano, St Jude Medical, Qualimed, and Xeltis, outside the submitted work. Publisher Copyright: © 2020, Springer-Verlag GmbH Germany, part of Springer Nature.

Keywords: Aspirin-free antiplatelet strategies, Chronic kidney disease, DAPT, Impaired renal function, Percutaneous coronary intervention, Ticagrelor

Local EPrints ID: 439768

URI: http://eprints.soton.ac.uk/id/eprint/439768

DOI: doi:10.1007/s00392-019-01586-9

ISSN: 1861-0684

PURE UUID: 698d9f08-af7d-42a7-bf4d-af7c37ad1754

ORCID for Nicholas Curzen: orcid.org/0000-0001-9651-7829

Date deposited: 01 May 2020 16:40

Last modified: 16 Apr 2024 01:39